<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04036084</url>
  </required_header>
  <id_info>
    <org_study_id>APHP180325</org_study_id>
    <nct_id>NCT04036084</nct_id>
  </id_info>
  <brief_title>Development of New Biomarkers With Magnetic Resonance Imaging for Longitudinal Studies in CADASIL Angiopathy</brief_title>
  <acronym>BIOMRI_CADA</acronym>
  <official_title>Développement de Nouveaux Biomarqueurs en Imagerie Par résonance magnétique Pour Les études Longitudinales Dans l'Angiopathie CADASIL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and&#xD;
      Leukoencephalopathy) is an cerebral microangiopathy secondary to mutations in the NOTCH3 gene&#xD;
      located on chromosome 19. This disease is the most frequent of the hereditary vascular&#xD;
      leukoencephalopathies.&#xD;
&#xD;
      CADASIL begins between the ages of 20 and 40 with the appearance of hyper-signs of brain&#xD;
      white matter visible on T2 sequences in magnetic resonance imaging (MRI). Before the age of&#xD;
      30, patients are most often asymptomatic. The disease is then responsible for different&#xD;
      neurological manifestations:&#xD;
&#xD;
        1. Migraine attacks with aura occur on average in one in three patients, most often at the&#xD;
           beginning of the course of the disease, sometimes even before the appearance of MRI&#xD;
           abnormalities;&#xD;
&#xD;
        2. Transient ischemic strokes or strokes associated with small cerebral infarcts occur most&#xD;
           frequently after the age of 50-60 years in more than two out of three patients;&#xD;
&#xD;
        3. Mood disorders are reported by one in three patients in the same age group;&#xD;
&#xD;
        4. Cognitive disorders that affect executive functions, especially after the age of 60,&#xD;
           until the stage of severe dementia associated with walking disorders are observed during&#xD;
           the course of the disease.&#xD;
&#xD;
      To date, there is no treatment whose efficacy has been proven in CADASIL. Various studies&#xD;
      have shown that the accumulation of the most destructive brain tissue lesions at the&#xD;
      subcortical level was closely correlated in CADASIL with the clinical severity of patients&#xD;
      (motor and cognitive disability). It is now possible to measure microstructural changes in&#xD;
      brain tissue in diffusion imaging during the course of the disease, even before significant&#xD;
      clinical changes are detected.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2019</start_date>
  <completion_date type="Anticipated">January 6, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 6, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intra-axonal</measure>
    <time_frame>1 year</time_frame>
    <description>Intra-axonal volume fraction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extra-axonal</measure>
    <time_frame>1 year</time_frame>
    <description>Extra-axonal volume fraction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intra-myelinic edema</measure>
    <time_frame>1 year</time_frame>
    <description>Volume fraction of intra-myelinic edema</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microvascular compartment fraction measured using diffusion MRI (IVIM)</measure>
    <time_frame>1 year</time_frame>
    <description>Measures of the Flowing blood volume fraction (corresponding to slow intra-voxel incoherent motion (IVIM) of water molecules in the cerebral microvasculature at voxel level)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>variation</measure>
    <time_frame>1 year</time_frame>
    <description>Overall variation of cerebral blood flow over 20 and 40 seconds stimulations (area under a curve)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood flow</measure>
    <time_frame>1 year</time_frame>
    <description>Maximum cerebral blood flow measured over 20 and 40 seconds stimulations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slope</measure>
    <time_frame>1 year</time_frame>
    <description>Slope of the regression curve when cerebral blood flow is measured 15 and 35 seconds after the onset of the stimulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dynamics of the cerebral blood</measure>
    <time_frame>1 year</time_frame>
    <description>Dynamics of the cerebral blood flow curve between 15 and 35 seconds (model with dual component responses; fast (before 20 seconds) and slow (after 20 seconds))</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cadasil</condition>
  <condition>Angiopathy; Cerebral</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Patients with CADASIL disease : Diagnosis confirmed by the detection of a pathogenic mutation in the NOTCH3 gene characteristic of CADASIL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cerebral Magnetic resonance imaging (MRI)</intervention_name>
    <description>Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Inclusion Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Month 1 Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Year 1</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        CADASIL patients with a proven NOTCH3 mutation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients&#xD;
&#xD;
          -  Age from 18 to 80 years&#xD;
&#xD;
          -  Confirmed diagnosis (detection of a pathogenic mutation of the NOTCH3 gene)&#xD;
&#xD;
          -  Detailed clinical and MRI assessment of the disease (follow-up at the CERVCO)&#xD;
             including Rankin score &lt;4&#xD;
&#xD;
          -  Any contraindication to MRI or EEG examination (claustrophobia, presence of material&#xD;
             with magnetic properties)&#xD;
&#xD;
          -  Social security insurance&#xD;
&#xD;
          -  Written consent.&#xD;
&#xD;
        Controls&#xD;
&#xD;
          -  Age from 18 to 80 years&#xD;
&#xD;
          -  No history of neurological or psychiatric diseases&#xD;
&#xD;
          -  No history of migraine with aura&#xD;
&#xD;
          -  No history of vascular disease (peripheral arteries, heart, brain)&#xD;
&#xD;
          -  No known or treated diabetes&#xD;
&#xD;
          -  No known or treated hypercholesterolemia&#xD;
&#xD;
          -  Social security insurance&#xD;
&#xD;
          -  Written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients&#xD;
&#xD;
          -  Patients with a contraindication to MRI or EEG examination (claustrophobia, material&#xD;
             with magnetic properties: pacemaker, ferromagnetic material ...)&#xD;
&#xD;
          -  For MRI examination of neurovascular coupling: Patients with a treatment that may&#xD;
             interfere with neurovascular coupling (in particular any treatment with non-steroidal&#xD;
             anti-inflammatory drugs, psychotropic drugs, antihypertensive agents or statins)&#xD;
&#xD;
          -  Patients without a social security insurance&#xD;
&#xD;
          -  Patients under the age of 18 or over 80 at the time of the first visit&#xD;
&#xD;
          -  Patients unable to give their informed consent&#xD;
&#xD;
          -  Person referred to in Articles L. 1121-5 to L. 1121-8 and L. 1122-12 of the Public&#xD;
             Health Code, defined by:&#xD;
&#xD;
               -  Pregnant, parturient or nursing woman&#xD;
&#xD;
               -  Person deprived of liberty by judicial or administrative decision&#xD;
&#xD;
               -  Person hospitalized without consent and not subject to a legal protection&#xD;
                  measure, and person admitted to a health or social institution for purposes other&#xD;
                  than research&#xD;
&#xD;
               -  Minor&#xD;
&#xD;
               -  Adult under legal protection measure (guardianship, guardianship or court order),&#xD;
                  an adult unable to express their consent and not subject to a protective measure&#xD;
&#xD;
               -  Person submitted to an exclusion period for another research (washout period)&#xD;
&#xD;
        Controls&#xD;
&#xD;
          -  Subject with a contraindication to MRI or EEG examination (claustrophobia, material&#xD;
             with magnetic properties: pacemaker, ferromagnetic material ...)&#xD;
&#xD;
          -  For MRI examination of neurovascular coupling: Subject with a treatment that may&#xD;
             interfere with neurovascular coupling (in particular any treatment with non-steroidal&#xD;
             anti-inflammatory drugs, psychotropic drugs, antihypertensive agents or statins)&#xD;
&#xD;
          -  Subject without a social security insurance&#xD;
&#xD;
          -  Subject under the age of 18 or over 80 years at the time of the first visit&#xD;
&#xD;
          -  Patients unable to give their informed consent&#xD;
&#xD;
          -  Person referred to in Articles L. 1121-5 to L. 1121-8 and L. 1122-12 of the Public&#xD;
             Health Code, defined by:&#xD;
&#xD;
               -  Pregnant, parturient or nursing woman&#xD;
&#xD;
               -  Person deprived of liberty by judicial or administrative decision&#xD;
&#xD;
               -  Person hospitalized without consent and not subject to a legal protection&#xD;
                  measure, and person admitted to a health or social institution for purposes other&#xD;
                  than research&#xD;
&#xD;
               -  Minor&#xD;
&#xD;
               -  Adult under legal protection measure (guardianship, guardianship or court order),&#xD;
                  an adult unable to express their consent and not subject to a protective measure&#xD;
&#xD;
               -  Person submitted to an exclusion period for another research study (washout&#xD;
                  period)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hugues CHABRIAT, MD, PhD</last_name>
    <phone>149952597</phone>
    <phone_ext>+33</phone_ext>
    <email>hugues.chabriat@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathalie GASTELLIER, PhD</last_name>
    <phone>149956872</phone>
    <phone_ext>+33</phone_ext>
    <email>nathalie.gastellier@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lariboisiere hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie GASTELLIER, PhD</last_name>
      <phone>149956872</phone>
      <phone_ext>+33</phone_ext>
      <email>nathalie.gastellier@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>matthieu RESCHE-RIGON, MD-PhD</last_name>
      <phone>142499742</phone>
      <phone_ext>+33</phone_ext>
      <email>matthieu.resche-rigon@univ-paris-diderot.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 15, 2019</study_first_submitted>
  <study_first_submitted_qc>July 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>CADASIL</mesh_term>
    <mesh_term>Dementia, Multi-Infarct</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

